Standard

Frizzled-7 is required for Wnt signaling in gastric tumors with and without Apc mutations. / Flanagan, Dustin; Barker, Nick; Di Costanzo, Natasha S; Mason, Elizabeth Anne; Gurney, Austin; Meniel, Valerie S; Koushyar, Sarah; Austin, Chloe R; Pearson, Helen B; Boussioutas, Alex; Clevers, Hans; Phesse, Toby J; Vincan, Elisabeth.

In: Cancer Research, 08.01.2019.

Research output: Contribution to journal/periodicalArticleScientificpeer-review

Harvard

Flanagan, D, Barker, N, Di Costanzo, NS, Mason, EA, Gurney, A, Meniel, VS, Koushyar, S, Austin, CR, Pearson, HB, Boussioutas, A, Clevers, H, Phesse, TJ & Vincan, E 2019, 'Frizzled-7 is required for Wnt signaling in gastric tumors with and without Apc mutations' Cancer Research. DOI: 10.1158/0008-5472.CAN-18-2095

APA

Flanagan, D., Barker, N., Di Costanzo, N. S., Mason, E. A., Gurney, A., Meniel, V. S., ... Vincan, E. (2019). Frizzled-7 is required for Wnt signaling in gastric tumors with and without Apc mutations. DOI: 10.1158/0008-5472.CAN-18-2095

Vancouver

Flanagan D, Barker N, Di Costanzo NS, Mason EA, Gurney A, Meniel VS et al. Frizzled-7 is required for Wnt signaling in gastric tumors with and without Apc mutations. Cancer Research. 2019 Jan 8. Available from, DOI: 10.1158/0008-5472.CAN-18-2095

Author

Flanagan, Dustin ; Barker, Nick ; Di Costanzo, Natasha S ; Mason, Elizabeth Anne ; Gurney, Austin ; Meniel, Valerie S ; Koushyar, Sarah ; Austin, Chloe R ; Pearson, Helen B ; Boussioutas, Alex ; Clevers, Hans ; Phesse, Toby J ; Vincan, Elisabeth. / Frizzled-7 is required for Wnt signaling in gastric tumors with and without Apc mutations. In: Cancer Research. 2019

BibTeX

@article{22c6419be3f64db38a244ca99a028906,
title = "Frizzled-7 is required for Wnt signaling in gastric tumors with and without Apc mutations",
abstract = "A subset of gastric cancer (GC) patients have mutations in genes that participate in or regulate Wnt signaling at the level of ligand (Wnt) receptor (Fzd) binding. Moreover, increased Fzd expression is associated with poor clinical outcome. Despite these findings, there are no in vivo studies investigating the potential of targeting Wnt receptors for treating GC, and the specific Wnt receptor transmitting oncogenic Wnt signaling in GC is unknown. Here we use inhibitors of Wnt/Fzd (OMP-18R5/Vantictumab) and conditional gene deletion to test the therapeutic potential of targeting Wnt signaling in preclinical models of intestinal-type gastric cancer and ex vivo organoid cultures. Pharmacological targeting of Fzd inhibited the growth of gastric adenomas in vivo. We identified Fzd7 to be the predominant Wnt receptor responsible for transmitting Wnt signaling in human gastric cancer cells and mouse models of GC, whereby Fzd7-deficient cells were retained in gastric adenomas but were unable to respond to Wnt signals and consequently failed to proliferate. Genetic deletion of Fzd7 or treatment with Vantictumab was sufficient to inhibit the growth of gastric adenomas with or without mutations to Apc. Vantictumab is currently in phase Ib clinical trials for advanced pancreatic, lung, and breast cancer. Our data extend the scope of patients that may benefit from this therapeutic approach as we demonstrate that this drug will be effective in treating gastric cancer patients regardless of Apc mutation status.",
author = "Dustin Flanagan and Nick Barker and {Di Costanzo}, {Natasha S} and Mason, {Elizabeth Anne} and Austin Gurney and Meniel, {Valerie S} and Sarah Koushyar and Austin, {Chloe R} and Pearson, {Helen B} and Alex Boussioutas and Hans Clevers and Phesse, {Toby J} and Elisabeth Vincan",
note = "Copyright {\circledC}2019, American Association for Cancer Research.",
year = "2019",
month = "1",
day = "8",
doi = "10.1158/0008-5472.CAN-18-2095",
language = "English",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",

}

RIS

TY - JOUR

T1 - Frizzled-7 is required for Wnt signaling in gastric tumors with and without Apc mutations

AU - Flanagan,Dustin

AU - Barker,Nick

AU - Di Costanzo,Natasha S

AU - Mason,Elizabeth Anne

AU - Gurney,Austin

AU - Meniel,Valerie S

AU - Koushyar,Sarah

AU - Austin,Chloe R

AU - Pearson,Helen B

AU - Boussioutas,Alex

AU - Clevers,Hans

AU - Phesse,Toby J

AU - Vincan,Elisabeth

N1 - Copyright ©2019, American Association for Cancer Research.

PY - 2019/1/8

Y1 - 2019/1/8

N2 - A subset of gastric cancer (GC) patients have mutations in genes that participate in or regulate Wnt signaling at the level of ligand (Wnt) receptor (Fzd) binding. Moreover, increased Fzd expression is associated with poor clinical outcome. Despite these findings, there are no in vivo studies investigating the potential of targeting Wnt receptors for treating GC, and the specific Wnt receptor transmitting oncogenic Wnt signaling in GC is unknown. Here we use inhibitors of Wnt/Fzd (OMP-18R5/Vantictumab) and conditional gene deletion to test the therapeutic potential of targeting Wnt signaling in preclinical models of intestinal-type gastric cancer and ex vivo organoid cultures. Pharmacological targeting of Fzd inhibited the growth of gastric adenomas in vivo. We identified Fzd7 to be the predominant Wnt receptor responsible for transmitting Wnt signaling in human gastric cancer cells and mouse models of GC, whereby Fzd7-deficient cells were retained in gastric adenomas but were unable to respond to Wnt signals and consequently failed to proliferate. Genetic deletion of Fzd7 or treatment with Vantictumab was sufficient to inhibit the growth of gastric adenomas with or without mutations to Apc. Vantictumab is currently in phase Ib clinical trials for advanced pancreatic, lung, and breast cancer. Our data extend the scope of patients that may benefit from this therapeutic approach as we demonstrate that this drug will be effective in treating gastric cancer patients regardless of Apc mutation status.

AB - A subset of gastric cancer (GC) patients have mutations in genes that participate in or regulate Wnt signaling at the level of ligand (Wnt) receptor (Fzd) binding. Moreover, increased Fzd expression is associated with poor clinical outcome. Despite these findings, there are no in vivo studies investigating the potential of targeting Wnt receptors for treating GC, and the specific Wnt receptor transmitting oncogenic Wnt signaling in GC is unknown. Here we use inhibitors of Wnt/Fzd (OMP-18R5/Vantictumab) and conditional gene deletion to test the therapeutic potential of targeting Wnt signaling in preclinical models of intestinal-type gastric cancer and ex vivo organoid cultures. Pharmacological targeting of Fzd inhibited the growth of gastric adenomas in vivo. We identified Fzd7 to be the predominant Wnt receptor responsible for transmitting Wnt signaling in human gastric cancer cells and mouse models of GC, whereby Fzd7-deficient cells were retained in gastric adenomas but were unable to respond to Wnt signals and consequently failed to proliferate. Genetic deletion of Fzd7 or treatment with Vantictumab was sufficient to inhibit the growth of gastric adenomas with or without mutations to Apc. Vantictumab is currently in phase Ib clinical trials for advanced pancreatic, lung, and breast cancer. Our data extend the scope of patients that may benefit from this therapeutic approach as we demonstrate that this drug will be effective in treating gastric cancer patients regardless of Apc mutation status.

U2 - 10.1158/0008-5472.CAN-18-2095

DO - 10.1158/0008-5472.CAN-18-2095

M3 - Article

JO - Cancer Research

T2 - Cancer Research

JF - Cancer Research

SN - 0008-5472

ER -

ID: 9361007